HAO · Haoxi Health Technology Limited

Haoxi Health Technology Limited, an online marketing solutions provider focused on healthcare advertisers in China, released unaudited condensed consolidated financial statements for the six months ended December 31, 2025, showing revenue growth to $33.8 million from $24.0 million in the prior year period, driven by higher demand from existing customers and strategic shift to domestic operations after closing loss-making overseas business. Gross profit improved significantly to $1.6 million (4.72% margin) from $0.5 million (2.01% margin), reflecting better cost management on traffic purchases from platforms like ByteDance. However, operations swung to a $6.6 million loss from a minor loss, exacerbated by sharp rises in general and administrative expenses to $7.2 million (up 1308%), mainly a $6.0 million provision for credit losses on prepaid advertising and third-party loans, plus $0.9 million impairment on intangible assets due to external environment changes and internal operations shifts. Net loss reached $6.9 million, with diluted EPS at $(1.53), compared to $(0.23) million and $(3.20) last year, adjusted for a January 2025 reverse share split. Balance sheet reflects $6.8 million cash (down from $8.6 million at June 30, 2025), total assets of $20.7 million, and equity of $16.0 million after turning to accumulated deficit of $2.3 million. Cash burn persisted with $2.3 million used in operations, $4.5 million in investing (convertible bond purchase), offset by $4.9 million financing inflows from follow-on offerings including $6.2 million net proceeds and warrant exercises. Management notes reliance on ByteDance traffic, customer count drop to 307 from 389, and plans for additional capital amid expected negative cash flows, believing current liquidity suffices for 12 months but highlighting growth financing needs.